Tafasitamab is a humanised monoclonal antibody targeting CD19, an antigen expressed on the surface of B cells and so involved in B cell malignancies, such as DLBCL. Credit: CoRus13 via Wikimedia.

has announced it has signed a collaboration and license agreement with the US company to continue the global development and commercialisation of the former鈥檚 tafasitamab (MOR208) for B-cell malignancies.

According to the terms of the deal, will receive a $750m upfront payment and a $150m equity investment in new American Depository Shares at a premium share price from Incyte.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, the German company will eligible to receive milestone payments of up $1.1bn, as well as tiered royalties on non-US net sales of tafasitamab.

The companies will co-commercialise tafasitamab in the US and share profits and losses equally, however MorphoSys will lead the commercialisation strategy. Outside of the US, Incyte will have exclusive commercialisation rights over the drug.

Focusing on development, Incyte will be responsible for 55% of associated costs, while MorphoSys will foot the remaining 45% of the development bill.

Tafasitamab is a humanised monoclonal antibody targeting CD19, an antigen expressed on the surface of B cells and so involved in B cell malignancies. MorphoSys submitted a biologics license application for the drug to the US Food and Drug Administration, and is expecting the drug to be approved in relapsed or refractory diffuse large B cell lymphoma (DLBCL) this year.

The companies have agreed to continue focus drug鈥檚 development in the DLBCL space, but also study its efficacy and safety in CLL, follicular lymphoma (FL) and marginal zone lymphoma (MZL).

Incyte will cover 100% of future development costs outside of the US and will be responsible for all new FL and MZL studies, as well as studies that combine tafasitamab with its P13k-delta inhibitor parsaclisib (INCB50465). While MorphoSys will continue to be solely responsible for ongoing studies in non-Hodgkin lymphoma, CLL and relapsed or refractory and frontline DLBCL.

MorphoSys CEO Jean-Paul Kress said: 鈥淭he global partnership with Incyte is an important step towards unlocking the full potential of tafasitamab and achieving our goal of rapidly bringing tafasitamab to patients inside and outside of the US.

Incyte CEO Herv茅 Hoppenot echoed this sentiment, saying: 鈥淏ringing together Incyte鈥檚 expertise and MorphoSys鈥� commitment to innovation will allow us to make tafasitamab widely available to patients with cancer, upon approval.

鈥淲e look forward to collaborating closely with the team at MorphoSys and adding tafasitamab to our portfolio of oncology candidates as part of our commitment to bringing new, advanced treatment options to patients and the clinical community around the world.鈥�

The licensing agreement is still subject to clearance by the US, German and Austrian antitrust authorities.